Related Experiment Video

Updated: May 29, 2026

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
07:28

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry

Published on: October 29, 2020

Pharmacokinetic and pharmacodynamic evaluation of tigecycline

Helen Giamarellou1, Garyphallia Poulakou

  • 1Head, 6th Department of Internal Medicine, Hygeia Hospital Professor of Internal Medicine and Infectious Diseases, Athens, Greece. e.giamarellou@hygeia.gr

Expert Opinion on Drug Metabolism & Toxicology
|October 1, 2011
PubMed
Abstract

Insights

Tigecycline is a crucial antibiotic against drug-resistant bacteria. Further pharmacokinetic/pharmacodynamic (PK/PD) studies are needed to redefine its role and expand its use beyond current indications, especially for challenging lung infections.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) organisms necessitates novel antimicrobial agents.
  • Tigecycline, a first-in-class glycylcycline, exhibits broad-spectrum activity against resistant pathogens, offering potential for expanded therapeutic applications.
  • Expanded evaluation of tigecycline's pharmacokinetics/pharmacodynamics (PK/PD) is crucial for optimizing its clinical utility.

Purpose of the Study:

  • To review and synthesize recent advancements in understanding tigecycline's PK/PD.
  • To identify areas where knowledge has been strengthened or challenged.
  • To explore the potential for expanding tigecycline's approved indications.

Main Methods:

  • Literature review focusing on recent studies of tigecycline PK/PD.
  • Analysis of PK data in patients with various infections (skin, intra-abdominal, pneumonia).
  • Examination of clinical trial data linking tigecycline exposure to outcomes.

Main Results:

  • New PK information is available for tigecycline in specific infection types.
  • Clinical trial data provides insights into the relationship between tigecycline exposure and patient outcomes.
  • The lung presents a challenging site for tigecycline PK/PD due to prevalent resistant organisms like Acinetobacter baumannii and carbapenemase-producing Klebsiella pneumoniae.

Conclusions:

  • Tigecycline remains a last-resort option for MDR pathogens.
  • Intensive PK/PD studies are required to redefine its clinical role and explore dose escalation or combination therapies.
  • Off-label use of tigecycline for ventilator-associated pneumonia highlights the need for further PK/PD research in this area.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...